Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by HPLC-UV. Population pharmacokinetic modelling was conducted using Pmetrics. Empiric dose of 4 g IV 6- and 8-hourly were simulated for 50 and 100% fT > MIC and the probabil-ity of target attainment (PTA) and the fractional target attainment (FTA) determined. Results: A two-compartment model was designed to describe the pharmacokinetics of critically ill Brazillian patients. Clearance and volume of distribution were (mean ± SD) 3.33 ± 1.24 L h−1 an...
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in criti...
Introduction: The aim of this study was to explore the impact of augmented creatinine clearance and ...
Our study aimed to describe the population pharmacokinetics (PK) of piperacillin and tazobactam in p...
There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australia...
The objectives of this study were (i) to compare the plasma concentration-time profiles for first-do...
Free to read on publisher's website The treatment of infections in critically ill obese and morbidly...
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in criti...
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients....
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients w...
Changes in the pharmacokinetics of piperacillin in febrile neutropenic patients have been reported t...
There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australia...
Background: Sustained low-efficiency dialysis (SLED), is increasingly being used in intensive care u...
OBJECTIVES: The study aimed to characterize the pharmacokinetics (PK) of four β-lactams (piperacilli...
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients w...
BACKGROUND AND OBJECTIVES: Although dose optimization studies have been performed for piperacillin a...
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in criti...
Introduction: The aim of this study was to explore the impact of augmented creatinine clearance and ...
Our study aimed to describe the population pharmacokinetics (PK) of piperacillin and tazobactam in p...
There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australia...
The objectives of this study were (i) to compare the plasma concentration-time profiles for first-do...
Free to read on publisher's website The treatment of infections in critically ill obese and morbidly...
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in criti...
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients....
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients w...
Changes in the pharmacokinetics of piperacillin in febrile neutropenic patients have been reported t...
There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australia...
Background: Sustained low-efficiency dialysis (SLED), is increasingly being used in intensive care u...
OBJECTIVES: The study aimed to characterize the pharmacokinetics (PK) of four β-lactams (piperacilli...
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients w...
BACKGROUND AND OBJECTIVES: Although dose optimization studies have been performed for piperacillin a...
Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in criti...
Introduction: The aim of this study was to explore the impact of augmented creatinine clearance and ...
Our study aimed to describe the population pharmacokinetics (PK) of piperacillin and tazobactam in p...